Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.43 |
| ▸ | ITGAL | P20701 | 3/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728734 | 0.81 | CHRM4 (0.51) | HTR3A | |
| SCHEMBL239367 | 0.78 | HTR3A (0.49) | HTR3AAKR1C3CXCR3 | |
| SCHEMBL10833510 | 0.77 | HTR3A (0.66) | HTR3A | |
| SCHEMBL28758769 | 0.77 | HTR3A (0.48) | HTR3AMAPTCXCR3 | |
| SCHEMBL1730249 | 0.76 | HTR3A (0.42) | HTR3A | |
| SCHEMBL21462555 | 0.76 | DCK (0.47) | MAPTPDE10AITGB2ICAM1ITGAL | |
| SCHEMBL237961 | 0.76 | PDE10A (0.64) | HTR3APDE10APDE2APDE1BPDE4D | |
| SCHEMBL23327566 | 0.75 | MAPT (0.41) | MAPTPDE10AITGB2ICAM1ITGAL | |
| SCHEMBL237973 | 0.75 | HTR3A (0.46) | HTR3ACXCR3 | |
| SCHEMBL23762131 | 0.75 | HTR3A (0.72) | HTR3AMAPTCXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
| EP-1633735-B1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| CN-1812980-A | Piperidinyl-and piperazinyl-alkylcarbamate derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2006-08-02 | — | — | CN | disclosed |
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| EP-1633735-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004099176-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | CLCN2, CNR2, RCC2 | HTR3A 2346/4885MAPT 4103/4885PDE10A 944/4885 |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTR3A 2303/4885MAPT 3778/4885PDE10A 1290/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | HTR3A 1876/4885MAPT 3841/4885PDE10A 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.